News

GSK manufacturing will take hit in cost-cutting move

GlaxoSmithKline's manufacturing network will take a hit as the company cuts costs in the face of falling revenues. The U.K. drugmaker was shy on details but said in an earnings release Wednesday that it needed to "rescale" R&D and manufacturing, as well as other operations. It reported a 3% revenue decline for its third quarter.

Repackager mistakenly puts some ibuprofen bottles into naproxen boxes

According to an FDA Medwatch alert, drug repackager Contract Packaging Resources is voluntarily recalling 11,640 boxes of Assured brand naproxen sodium tablets in the 220 mg dose because some of the cartons actually contain bottles of 200 mg ibuprofen softgels instead.

Argos starts work on $57M plant in North Carolina

Argos Therapeutics, which has a personalized immunotherapy drug to treat renal cell carcinoma in trials, has kicked off work on a $57 million manufacturing facility in North Carolina. The biotech will get nearly $10 million in public support for the project.

Mylan recalls blood pressure med, following recalls of generic by two other drugmakers

Another drugmaker is having to recall metoprolol succinate extended release tablets, a generic for AstraZeneca hypertension drug Toprol XL. This time it is Mylan and the recall is for nearly 16,000 bottles of the beta blocker.

UPDATED: Janssen recalls 13,500 bottles of Xarelto because of contamination

Johnson & Johnson's Janssen unit is recalling 13,500 bottles of its top-selling anticoagulant Xarelto because of microbial contamination.

FDA will start the new year with its Office of Quality in place

The Office of Pharmaceutical Quality will finally open Jan. 1, and the FDA's Janet Woodcock will serve as its first acting director.

BARDA calls on Novartis, GSK, Emergent to pitch in with Ebola drug

The U.S. government invested $440 million in three vaccine plants in the U.S. in 2012 with the proviso that if something like a pandemic occurred, it could call on them to produce drugs that it required. With Ebola spreading, those calls have now been made.

Canada cuts Apotex a break on some banned drugs

More than three dozen drugs and APIs that were originally banned by health regulators in Canada will be allowed into the country because they are medically necessary.

Lilly closing a Puerto Rico plant next year but investing in another

Puerto Rico, which has seen a number of plant closings recently, is facing another. Eli Lilly said it will close a facility in Guayama next year and put it up for sale.

Italy's Cosmo to build manufacturing plant in Ireland

U.S. drugmakers are not the only ones building plants in Ireland to take advantage of the lower taxes and incentives afforded there. Italian specialty drugmaker Cosmo says that is what it intends to do.

FDA cites animal drug compounder for selling copies of Novartis' Capstar

The FDA, which has been corralling human drug compounders, is also keeping track of some focused on animal drugs.

Court orders Indian drugmaker to destroy $11M worth of unapproved drugs

In May, the FDA sent U.S. marshals into a warehouse to seize $11 million worth of drugs, everything from ear drops to urea cream, from an Indian company that the agency said were unapproved. Now the company is going to have to destroy them all while the FDA watches.

Abbott opens third nutrition plant this year

Abbott Laboratories, which has made a large bet on its global nutrition business, is in the final throw of a manufacturing triple play. The Chicago-area company this week opened a nutrition products plant in India after opening plants in the U.S. and China several months ago.

Hospira recalls two dozen lots of saline solution

Hospira is recalling "certain lots of several products in its LifeCare line of flexible intravenous solutions due to the potential for leakage." But the description does not get to the depth and breadth of the recall, which is for 54 lots of nearly a dozen products. That includes two dozen lots of saline solution in the 1000-mL size, an essential hospital product that has been in short supply for months.

FDA bans maker of suspect Chinese heparin

The FDA has taken steps against a Chinese heparin maker it says is using potentially tainted raw supplies and which refused to let inspectors get a good look at its plants or records so that it could find out for sure.

Indian drugmakers scramble to prevent shortages of HIV/AIDS meds

Some Indian companies that had put off production of HIV/AIDS meds while they waited for the government to sign contracts are now having to seriously ramp up because of shortages of some meds, Reuters reports.

UPDATED: Novartis faces technical issues on $150M plant in Russia

Construction of a $150 million plant that Novartis is building near St. Petersburg in Russia has been halted because of "technical reasons," just short of completion.

FDA chastises Sun for weak follow-through on drug recalls

In March, Sun Pharmaceutical recalled more than 2,500 bottles of its diabetes treatment metformin HCl after a customer reported finding an epilepsy pill in one. The company said it was investigating the issue, but apparently not to the satisfaction of the FDA.

GSK adds jobs at North Carolina plant, expecting new drugs to take off

While GlaxoSmithKline's new drugs Anoro and Breo have yet to take flight like the company had hoped, the drugmaker has been expanding the North Carolina plant where it makes them and other respiratory drugs, expecting that they will.

Mapp, HHS scrambling to find ways to supercharge production of Ebola drug

With Ebola rampaging through West Africa and now having reached the U.S., U.S. officials and the maker of an experimental Ebola drug manufactured from cells grown in tobacco leaves, ZMapp, want to expand the drug's current production while also seeing if traditional mammalian-cell methods might be used to quickly scale up production of the drug.